Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 634 of 5804
-
Keytruda shows promise in shrinking untreatable bowel tumors
Disease control OngoingIn this study, the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancer will be assessed.
Phase: PHASE2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill shows promise for ulcerative colitis in major trial
Disease control CompletedThis is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of …
Phase: PHASE3 • Sponsor: Abivax S.A. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Stem cell shot may free kidney patients from lifelong pills
Disease control Recruiting nowThe study seeks to determine if patients with a pre-existing, well-functioning kidney transplant from a HLA-identical living donor can be withdrawn from immunosuppressive medications without compromising allograft function through hematopoietic stem cell (HPSC) infusion from the …
Phase: PHASE1 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Gene-Matched cancer therapy tested in 400 patients with aggressive tumors
Disease control Recruiting nowThis is a prospective, open-label navigational investigation designed to evaluate the feasibility of using molecular profile-based evidence to determine individualized cancer therapy for patients with aggressive malignancies. This is a non-randomized, histology-agnostic trial. Al…
Phase: PHASE1, PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
One-Time gene shot could free gaucher patients from lifelong infusions
Disease control Recruiting nowStudy J3Z-MC-OJAE is a Phase 1/2, multicenter, open-label, dose-finding study of LY3884961 evaluating the safety and tolerability in adults with peripheral manifestations of GD. Up to 3 dose levels of LY3884961 will be assessed in 3 dose-finding cohorts of 3 patients. Following …
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New triple therapy aims to control CLL without lifelong treatment
Disease control Recruiting nowTo learn if the combination of pirtobrutinib (also called LOXO-305), venetoclax, and obinutuzumab is safe and effective when given to patients with chronic lymphocytic leukemia (CLL) or Richter transformation (RT) who have not previously received treatment.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Poop pills to prevent transplant rejection? new trial tests fecal transplants in blood cancer patients
Prevention Recruiting nowThe aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD). The hypothesis of this study is that alloge…
Phase: PHASE2 • Sponsor: University Hospital, Clermont-Ferrand • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC
-
New Vaccine-Immunotherapy combo targets breast cancer brain metastases
Disease control Recruiting nowThis phase IIa trial studies how well dendritic cell vaccines against Her2/Her3 and pembrolizumab work for the treatment of triple negative breast cancer or HER2+ breast cancer or HER+ Breast cancer that has spread to the brain (brain metastasis). Dendritic cell vaccines work by …
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Could less be more? new trial tailors endometrial cancer treatment to tumor type
Disease control Recruiting nowThis protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAP…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Magnetic gut reroute shows promise for diabetes and weight loss
Disease control CompletedThe purpose of this clinical research study is to evaluate the feasibility of the GT Metabolic Solutions DI Bio-fragmentable Magnetic Anastomosis System (MAGNET System, DI Bio-fragmentable) for creation of a side-by-side anastomosis duodeno-ileostomy in obese adults.
Phase: NA • Sponsor: GT Metabolic Solutions, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New oral drug shows promise for painful skin condition
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week extension period.
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can exercise tweak tumor biology? new trial tests aerobic vs. resistance training in breast cancer
Disease control CompletedA recent consensus study suggested that understanding the impact of exercise on the tumor microenvironment and therapy effectiveness is paramount and should be considered as a research priority. Therefore, the research team intends to address some of the scientific challenges pro…
Phase: NA • Sponsor: Fundacao Champalimaud • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Arthritis drug shows promise against rare childhood brain tumor
Disease control Recruiting nowACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis. In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurren…
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New antibody shot aims to shield vulnerable patients from COVID-19
Prevention CompletedAZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19. The aim of the Phase I/III study (Parent Study) will be to evaluate the safety, efficacy and neutralizing activity …
Phase: PHASE2, PHASE3 • Sponsor: AstraZeneca • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug aims to halt scarring hair loss
Disease control CompletedAlopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known as cicatricial alopecia (CA), in which hair follic…
Phase: PHASE2 • Sponsor: Emma Guttman • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Love and safety: new study tests if relationship skills can cut HIV risk
Prevention Recruiting nowThe purpose of this study is to upgrade an existing relationship education and HIV prevention program. This program is designed for gay, bisexual, queer, and transgender and non-binary people who partner with cisgender men. This means the program is designed for gay, bisexual and…
Phase: NA • Sponsor: Northwestern University • Aim: Prevention
Last updated Jun 27, 2026 12:31 UTC
-
New hope for older myeloma patients: drug combo shows promise
Disease control OngoingThis is a multicenter, phase II, national, and open-label study to evaluate the efficacy and safety of two different combinations, iberdomide-dexamethasone (IBERDEX) and iberdomide-dexamethasone in combination with daratumumab (IBERDARADEX) in transplant ineligible newly diagnose…
Phase: PHASE2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Tiny Lung-Artery sensor could help heart failure patients live longer
Disease control ENROLLING_BY_INVITATIONThe purpose of this post-approval study (PAS) is to evaluate the long-term safety and effectiveness of the CardioMEMS™ HF System using real-world evidence (RWE) methods.
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could flickering lights and sounds slow Alzheimer's? MIT launches home device trial
Disease control Recruiting nowAlzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. The investigator's lab found that boosting gamma waves in AD mouse models using light and sound stimulation …
Phase: NA • Sponsor: Massachusetts Institute of Technology • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New combo attack on hard-to-treat lymphoma shows promise in early trial
Disease control Recruiting nowThe purpose of this research study is to test if a combination treatment of chimeric antigen receptor (CAR) T-cell therapy, Mosunetuzumab, and Polatuzumab Vedotin will result in tumor reduction.
Phase: PHASE2 • Sponsor: Lazaros Lekakis • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC